BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 11745206)

  • 21. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
    Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
    Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
    Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma.
    He WG; Yan Y; Tang W; Cai R; Ren G
    Oncotarget; 2017 Jun; 8(23):37730-37739. PubMed ID: 28465480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlation between typing of peripheral neuroblastic tumors and prognosis: a clinicopathologic study of 135 cases].
    YIN MZ; ZHANG ZD; MA J; SHEN P; CHEN JF; ZHANG HZ
    Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):151-5. PubMed ID: 21575383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.
    Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B
    Cancer; 1999 Jul; 86(2):349-63. PubMed ID: 10421272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.
    Gambini C; Conte M; Bernini G; Angelini P; Pession A; Paolucci P; Donfrancesco A; Veneselli E; Mazzocco K; Tonini GP; Raffaghello L; Dominici C; Morando A; Negri F; Favre A; De Bernardi B; Pistoia V
    Virchows Arch; 2003 Jun; 442(6):555-62. PubMed ID: 12709798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
    Suganuma R; Wang LL; Sano H; Naranjo A; London WB; Seeger RC; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Jarzembowski JA; Joshi VV; Navarro S; Peuchmaur M; Shimada H
    Pediatr Blood Cancer; 2013 Mar; 60(3):363-70. PubMed ID: 22744966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Peripheral neuroblastic tumors: anatomo pathological classification].
    Peuchmaur M
    Ann Pathol; 2004 Dec; 24(6):556-67. PubMed ID: 15785402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; Bennani-Othmani M; Sibai H; Itri M; Benchekroun S; Zamiati S
    Diagn Pathol; 2013 Feb; 8():39. PubMed ID: 23445749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
    Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular genetic abnormalities of N-myc and C-myc in pediatric neuroblastic tumors and clinical pathologic significance].
    Cai RQ; Zhou CJ; Sun QN; Ma XL; Wang M; Li Y; Wang DY; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):299-304. PubMed ID: 24004585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic and prognostic information obtained on fine-needle aspirates of primary neuroblastic tumors: Proposal for a cytology prognostic score.
    Klijanienko J; Couturier J; Brisse H; Pierron G; Fréneaux P; Berger F; Maciorowski Z; Sastre-Garau X; Michon J; Schleiermacher G
    Cancer Cytopathol; 2011 Dec; 119(6):411-23. PubMed ID: 21774092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and surgical outcome differences on the basis of pathology category in cervical neuroblastic tumors.
    Liu Q; Wang S; Chu P; Sun J; Jin Y; Guo Y; Ma X; He L; Su Y; Zhang J; Peng Y; Li Y; Zhang X; Sun N; Liu Z; Ni X
    J Pediatr Surg; 2022 Dec; 57(12):926-933. PubMed ID: 35961818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
    Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J
    Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.